- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
RADX
NASDAQ
Week ended 07 Aug 2026
Weekly Investor Report
Radiopharm Theranostics Limited American Depositary Shares · Healthcare · Biotechnology
Latest close
2.80 USD
-11.1%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -37.3% below the Trend Line and sits at 1.3% of its 52-week range. The latest completed week returned -11.1%, after a -35.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100.
Setup score
17
out of 100
Latest Close
2.80 USD
7 Aug 2026
1W Return
-11.1%
latest completed week
4W Return
-35.9%
short-term follow-through
12W Return
-40.6%
quarterly tape
Trend Breadth
17.3%
9 of 52 weeks active
Volume Ratio
1.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-11.1%
Latest completed week; four-week move -35.9%.
Indicator stack
10/10
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
52/100
32 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -37.3% below the Trend Line and sits at 1.3% of its 52-week range. The latest completed week returned -11.1%, after a -35.9% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1512-week average 0.09
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure3/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.15Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -35.9% over four weeks, -40.6% over 12 weeks, and -40.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year9
Trend breadth17.3%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.39Latest activity-pressure read.
Pressure change-414.3%Four-week change in activity pressure.
Leadership-50.35Latest relative-leadership reading.
RS change-98.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 67%
Model confidence 53%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength42/100Blend of value, momentum, and quality. Underlying universe rank 59; rank 1 is best.
Value46/100Relative valuation strength. Underlying universe rank 55; rank 1 is best.
Quality44/100Profitability and accounting quality. Underlying universe rank 57; rank 1 is best.
Momentum46/100Medium-term price momentum. Underlying universe rank 55; rank 1 is best.
Growth46/100Revenue and earnings growth. Underlying universe rank 55; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 6.1x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -233.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 1.1% Gross profit retained from each unit of revenue.
- Operating margin
- -1050.6% Operating profit retained from revenue.
- Free-cash-flow margin
- -1417.8% Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- - Net share repurchases relative to market value.
- Shareholder yield
- - Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.9x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment52/100
Weighted news tone is neutral across 32 relevant articles.
6 positive · 25 neutral · 1 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-82.8%Distance below the 52-week high.
13-week volatility9.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher9 of 2615 weeks finished lower.
Best week+17.8%Week of 15 May.
Worst week-19.9%Week of 24 Jul.
Latest week-11.1%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains5
Flat weeks2
Modest losses7
Sharp losses8
Recent vol9.3%13-week weekly-return volatility.
Base vol8.6%52-week weekly-return volatility.
Up/down split22/28Count of positive and negative weeks in the 52-week window.
Average skew6.5% / -6.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average2.6%
Trend breadth54.0%
Trend54.0%active weekly trend signals
MD77.0%positive activity pressure
RS44.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD64.0%positive activity pressure
RS62.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape19/100
Trend, activity pressure, participation, and risk combine to a 19/100 tape read.
Indicator analysis16/100Latest 12-week confirmation: trend 0/12, activity pressure 3/12, relative leadership 0/12.
Activity pressure 0.15; No reversal markers Factors43/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 50 Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Sentiment52/100Weighted news tone is neutral across 32 relevant articles.
RADX Stock Price and Chart — NASDAQ:RADX Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 2.80 USD | -11.1% | 4.47 USD | 5.01 USD | -0.39 | -50.35 | 327.6K | Off |
| 31 Jul 2026 | 3.15 USD | -11.3% | 4.54 USD | 5.03 USD | -0.11 | -41.92 | 784.3K | Off |
| 24 Jul 2026 | 3.55 USD | -19.9% | 4.61 USD | 5.05 USD | 0.13 | -34.99 | 1.6M | Off |
| 17 Jul 2026 | 4.43 USD | 1.4% | 4.68 USD | 5.07 USD | 0.18 | -20.78 | 130.3K | Off |
| 10 Jul 2026 | 4.37 USD | 0.0% | 4.70 USD | 5.08 USD | 0.12 | -25.38 | 70.7K | Off |
| 3 Jul 2026 | 4.37 USD | 8.7% | 4.70 USD | 5.09 USD | -0.03 | -24.29 | 92.6K | Off |
| 26 Jun 2026 | 4.02 USD | -9.7% | 4.71 USD | 5.10 USD | -0.15 | -29.93 | 132.0K | Off |
| 19 Jun 2026 | 4.45 USD | 4.2% | 4.73 USD | 5.11 USD | -0.06 | -26.44 | 94.8K | Off |
| 12 Jun 2026 | 4.27 USD | -1.2% | 4.73 USD | 5.12 USD | -0.13 | -27.97 | 88.1K | Off |
| 5 Jun 2026 | 4.32 USD | -5.7% | 4.74 USD | 5.13 USD | -0.06 | -26.08 | 159.7K | Off |
| 29 May 2026 | 4.58 USD | -1.1% | 4.76 USD | 5.14 USD | -0.19 | -25.71 | 62.5K | Off |
| 22 May 2026 | 4.63 USD | -1.7% | 4.78 USD | 5.15 USD | -0.35 | -23.21 | 150.3K | Off |
| 15 May 2026 | 4.71 USD | 17.8% | 4.80 USD | 5.15 USD | -0.50 | -21.48 | 402.2K | Off |
| 8 May 2026 | 4.00 USD | -9.3% | 4.88 USD | 5.16 USD | -0.64 | -33.74 | 223.2K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.